ClinicalTrials.gg
RecruitingNCT05688605Updated Sep 4, 2026

A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors

A Phase 1/2 interventional study of MRG003+HX008 in Advanced Solid Tumors, sponsored by Lepu Biopharma Co., Ltd.. Recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-04.

Sponsored by Lepu Biopharma Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Jun 2022, registered Jan 2023).
  • Started Jun 2022; still recruiting 4 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG003 in combination with HX008 in patients with EGFR-positive advanced or metastatic solid tumors.

Read the detailed description

This study consists of two parts: Phase I and Phase II. The objective of this study is to assess the safety and tolerability of MRG003 in combination with HX008 in patients with EGFR-positive advanced or metastatic solid tumors; and to explore the maximum tolerated dose (MTD) and to determine the recommended phase II dose (RP2D) of combination therapy; and to evaluate the preliminary efficacy, pharmacokinetics, and immunogenicity of combination therapy in the targeted study population.

02

Conditions studied

  • Advanced Solid Tumors

Keywords

  • MRG003
  • HX008
  • Antibody Drug Conjugate (ADC)
  • EGFR
  • Solid tumors
03

In context

Lead sponsor

Lepu Biopharma Co., Ltd. is the lead sponsor of 16 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing to sign the form and follow the requirements specified in the protocol.
  2. Aged 18 to 75 (including 18 and 75), both genders.
  3. ≥17
  4. ≥ 12 weeks.
  5. Patients with EGFR-positive advanced or solid tumors, including non-small cell lung cancer (NSCLC), squamous cell carcinoma of head and neck (SCCHN), and nasopharyngeal carcinoma (NPC).
  6. EGFR-positive determined by immunohistochemistry (except NSCLC, SCCHN and NPC).
  7. Patients must have according to the (RECIST v1.1).
  8. The score of for performance status is 0 or 1.
  9. No severe cardiac dysfunction.
  10. Acceptable liver, renal, and hematologic function.
  11. Patients with must use effective during the treatment and for 6 months after the last dose of treatment.

Exclusion criteria

Exclusion Criteria:

  1. History of to any component of the product.
  2. Prior treatment with chemotherapy, biological therapy, immunotherapy, radiotherapy, investigational drugs, attenuated , immunomodulators, inhibitors/inducers, antibody-drug conjugates, Received major surgery without complete recovery, etc.
  3. Treatment with MMAE/MMAF ADC drugs
  4. Central nervous system .
  5. Toxic reaction or abnormal value of laboratory test caused by previous anti-tumor treatment ≥ 2 ( v5.0)
  6. Presence of peripheral neuropathy ≥ Grade 2.
  7. Liver function Grade B or Grade C。
  8. Pleural and peritoneal effusion or pericardial effusion with clinical symptoms requiring drainage.
  9. Poorly controlled systemic diseases (hypertension and hyperglycemia, etc.)
  10. Evidence of active infection of , or .
  11. Patients with poorly controlled heart diseases
  12. History of ophthalmic abnormalities.
  13. History of severe skin disease requiring oral or intravenous therapy.
  14. History of interstitial pneumonia, radiation pneumonia, severe , severe pulmonary insufficiency, symptomatic bronchospasm, etc.
  15. Active, known or suspected disease or drug related immune disease or the disease history within the past 2 years.
  16. The patient is using or systemic hormone therapy.
  17. Patients with any past arteriovenous bleeding within 3 months or current history of coagulation disorder.
  18. Any VTE occurred within 6 months.
  19. Received allogeneic tissue/solid organ transplantation.
  20. Inoculate live vaccine within 30 days before the first dose.
  21. Patients with a positive serum pregnancy test or who are breast-feeding or who do not agree to take adequate measures during the treatment and for 180 days after the last dose of study treatment.
  22. History of other primary malignant tumor diseases.
  23. Investigator considers which not suitable to participate in the clinical trial
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    MRG003+HX008

    MRG003 will be administrated via intravenous infusion at 1.5, 2.0 mg/kg (MTD=2.5 mg/kg) once on Day 1 of every 3 weeks (21-day cycle). HX008 will be administrated via intravenous infusion at 3 mg/kg once on Day 1 of every 3 weeks (21-day cycle).

    Drug: MRG003+HX008

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD)

    MTD is the highest dose with the proportion of DLT less than 1/3

    Time frame: Within 21 days after the first dose of the last patient of the MTD group

  2. Recommended Phase II Dose (RP2D)

    The dose level of MRG003 recommended for further clinical studies based on assessment of the safety, efficacy and PK data from this study.

    Time frame: Baseline to study completion (up to 12 months)

  3. Objective Response Rate (ORR)

    ORR is defined as the proportions of patients with a complete response (CR) and partial response (PR). ORR will be assessed by investigator according to RECIST v1.1.

    Time frame: Baseline to study completion (up to 12 months)

Secondary outcomes

  1. Duration of Response (DOR)

    DOR is defined as the duration from the initial recording of objective disease response to the first onset of tumor progression, or death of any cause.

    Time frame: Baseline to study completion (up to 12 months)

  2. Disease Control Rate (DCR)

    DCR is defined as the proportion of subjects achieving CR, PR, and SD after treatment.

    Time frame: Baseline to study completion (up to 12 months)

  3. Progression Free Survival (PFS)

    PFS is defined as the duration from the start of treatment to the onset of tumor progression or death of any cause.

    Time frame: Baseline to study completion (up to 12 months)

  4. Overall Survival (OS)

    OS is defined as the duration from the start of treatment to death of any cause.

    Time frame: Baseline to study completion (up to 12 months)

  5. Immunogenicity (ADA)

    The proportion of patients with positive ADA results.

    Time frame: Baseline to 90 days after the last dose.

  6. Adverse Events (AEs)

    Any reaction, side effect, or untoward event that occurs during the course of the clinical trial whether or not the event is considered related to the study drug.

    Time frame: Baseline to 30 days after the last dose of study treatment

  7. Serious Adverse Events (SAEs)

    Adverse events that are difficult to deal with in clinical drug research

    Time frame: Baseline to 90 days after the last dose of study treatment

  8. PK parameters: concentration-time curve

    Plot of drug concentration changing with time after drug administration

    Time frame: Baseline to 90 days after the last dose.

07

Study locations

1 of 2 sites recruiting
08

References and documents

Publications

  • Ruan DY, Wang FH, Zhou Y, Xiang Y, Lin J, Liu L, Liu P, Tang L, Ma Y, Hou T, Chen Q, Li ZM, Han F, Qu S, Qiu S, Han C, Ma H, Su F, Gao J, Guo Y, Wu Z, Wu HJ, Zhao Y, Fang M, Hu M, Wu Y, Cui S, Li M, Zhao Q, Xu RH. Becotatug Vedotin Combined With Pucotenlimab in Platinum- and Immunotherapy-Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma. J Clin Oncol. 2026 Aug 25:JCO2600640. doi: 10.1200/JCO-26-00640. Online ahead of print. PubMed 42641116 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2022 (actual). Primary completion is estimated for Aug 2027, 62 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2023
First posted
Jan 18, 2023
StartActual
Jun 30, 2022
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2027
Last update
Sep 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05688605
Lead sponsor
Lepu Biopharma Co., Ltd.
Responsible party
Sponsor
First posted
Jan 18, 2023
Start date
Jun 30, 2022
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Sep 4, 2026

Study contacts

Program Director
Contact
clinicaltrials@miracogen.com.cn
86-21-61637960
Ruihua Xu, M.D.
principal investigator · Sun Yat-Sen University Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Becotatug vedotin · Pucotenlimab

Start the discussion